Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type i (IGF1R), in Japanese patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 3, 2012, Pages 407-414

  Murakami, Haruyasu ^a   Doi, Toshihiko ^b   Yamamoto, Nobuyuki ^a   Watanabe, Junichiro ^a   Boku, Narikazu ^a,c   Fuse, Nozomu ^b   Yoshino, Takayuki ^b   Ohtsu, Atsushi ^b   Otani, Satoru ^d   Shibayama, Kazuhiro ^d   Takubo, Takatoshi ^d   Loh, Elwyn ^e  

^a SHIZUOKA CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE HOSPITAL   (Japan)

^d Takeda Bio Development Center Ltd   (Japan)

^e AMGEN INC   (United States)

Author keywords

Clinical trial; Ganitumab; Gemcitabine; Insulin like growth factor receptor type 1; Phase 1

Indexed keywords

GANITUMAB; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; COHORT ANALYSIS; COLON CANCER; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; ESOPHAGUS CANCER; FATIGUE; FEVER; HEADACHE; HUMAN; INFUSION RELATED REACTION; JAPANESE; KIDNEY CANCER; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; RECTUM CANCER; SIDE EFFECT; SMALL INTESTINE CANCER; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; THYMUS CANCER; UTERUS CANCER; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; JAPAN; MALE; MIDDLE AGED; NEOPLASMS; RECEPTOR, IGF TYPE 1; TREATMENT OUTCOME;

EID: 84866418084     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1924-9     Document Type: Article

References (19)

1. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signaling. Nature 411:355-365
2. Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J (2000) High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. J Clin Endocrinol Metab 85:3653-3660
3. Sachdev D, Yee D (2007) Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6:1-12 (Pubitemid 46206663)
4. Macaulay VM (1992) Insulin-like growth factors and cancer. Br J Cancer 65:311-320
5. Werner H, Le Roith D (1996) The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 68:183-223
6. Werner H, Le Roith D (2000) New concepts in regulation and function of the insulin-like growth factors: implications for understanding normal growth and neoplasia. Cell Molec Life Sci 57:932-942 (Pubitemid 30461834)
7. Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B (1997) The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1332:F105-F126 (Pubitemid 27272620)
8. Weroha SJ, Haluska P (2008) IGF-1 receptor inhibitors in clinical trials - early lessons. J Mam Gland Biol Neopl 13:471-483
9. Ryan PD, Goss PE (2008) The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 13:16-24 (Pubitemid 351206693)
10. Beltran PJ, Mitchell P, Chung Y-A et al (2009) AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther 8:1095-1105
11. Tolcher AW, Sarantopoulos J, Patnaik A et al (2009) Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 27:5800-5807
12. Himpe E, Degaillier C, Coppens A, Kooijman R (2008) Insulinlike growth factor-1 delays Fas-mediated apoptosis in human neutrophils through the phosphatidylinositol-3 kinase pathway. J Endocrinol 199:69-80
13. Pollak M, Beamer W, Zhang J-C (1999) Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 17:383-390 (Pubitemid 29331788)
14. Hwa V, Oh Y, Rosenfeld RG (1999) The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 20: 761-787 (Pubitemid 30648894)
15. Chang YS, Gong K, Sun S et al (2002) Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clin Cancer Res 8:3796-3802 (Pubitemid 35424772)
16. Chang YS, Wang L, Suh Y-A et al (2004) Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. Oncogene 23:6569-6580 (Pubitemid 39265520)
17. McCaffery I, Tudor Y, Deng H et al (2011) Effect of baseline (BL) biomarkers on overall survival (OS) in metastatic pancreatic cancer (mPC) patients (pts) treated with ganitumab (GAN; AMG 479) or placebo (P) in combination with gemcitabine (G). J Clin Oncol 29(suppl):4041
18. Ikeda M, Okusaka T, Fukutomi A et al (2011) A phase 1b, openlabel study to evaluate the safety of ganitumab (AMG 479) in combination with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer. Presented at the 2011 European Multidisciplinary Cancer Congress, September 23-27, Stockholm (Abstr 6587)
19. Kindler HL, Richards DA, Stephenson J et al (2010) A placebocontrolled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC). J Clin Oncol 28(suppl):4035